Geographic Area
AstraZeneca Abandons Roxadustat’s US Future while Retaining Collaboration with FibroGen in China
FibroGen, roxadustat, China, Ultrasonography, AstraZeneca, Collaboration, chemotherapy-induced anemia, Retained
Johnson & Johnson Closes Bay Area R&D Facility, Plans New California Innovation Center
Research and Development, Johnson and Johnson, California, Central
Interchangeable Humira Biosimilar Simlandi Joins Market Battle with Unique High-Concentration Formula
Simlandi, interchangeable, Biosimilars, Market
Alvotech and Teva Settle with Johnson & Johnson for Stelara Biosimilar AVT04 in the US
Alvotech, Teva, Settlement and Resettlement, AVT04, United States
Pharma Executives of BMS, J&J, and Merck Confronted in Senate Hearing on Sky-High Drug Prices
United States, Prices, CEOs, Country, Johnson and Johnson, R&D, Merck
Headlight: PillPack Co-Founder Backs Mental Health Startup’s $18M Funding in Transformative Care Mission
PillPack, Amazona, Clinician, Practice Experience
I-Mab Transitions to US-focused Biotech with Divestment of Chinese Operations
I-Mab’s, United States, I-Mab, Surgical aspects
UPDATE: Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta
Cystic Fibrosis, Trikafta, vanza, Vertex, next-gen, Records
Updated: Novo Holdings pays $16.5B to take Catalent private and sells three manufacturing sites to Novo Nordisk
Holdings, Nordisk, deal, Acquisition (action), Investments